Date: October 1, 2026
Other Operational / Legal / Strategic Disclosures
Piramal Pharma Limited has disclosed the expiry and non-renewal of its commercial arrangement with Bayer Pharmaceuticals Private Limited (\"Bayer\").
Key Details of the Arrangement:
- The commercial arrangement, under which the Company provided sales and distribution support services to Bayer, is scheduled to expire on December 31, 2026.
- The arrangement will not be renewed beyond its current term and will conclude upon its natural expiry on December 31, 2026.
- The Company is working closely with Bayer to ensure a smooth and orderly transition of the activities currently undertaken under the arrangement.
Financial Impact Assessment:
- The arrangement primarily involved the provision of sales and distribution support services, for which the Company earned commission-based income.
- Revenue attributable to this arrangement accounts for less than 5% of the Company's consolidated revenue.
- As the arrangement is commission-based, the Company does not expect the non-renewal to have a material impact on its profitability or financial position.
Regulatory Context: